Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma

The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment

Anupam Rasayan India Limited, a leading custom synthesis and specialty chemicals company, has signed a definitive agreement to acquire a 43.3%–48.2% equity stake in Bliss GVS Pharma Limited, an India-based pharmaceutical formulations company. 

The transaction also includes an open offer to the public shareholders of Bliss GVS Pharma in accordance with regulatory requirements.

The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment, expanding its presence beyond specialty chemicals and custom synthesis into the broader healthcare and life sciences space.

The total acquisition consideration will be financed through a combination of Rs. 300 crore term loan and non-controlling, non-voting equity instruments for the remaining amount.

Bliss GVS Pharma Limited is known for its presence in women’s healthcare and suppository dosage formulations, with operations spanning domestic and international markets. 

The acquisition is expected to strengthen Anupam Rasayan’s diversification strategy while creating synergies across pharmaceuticals, specialty chemicals and CDMO opportunities.